Long-term Safety of Crizotinib in Chinese NSCLC Patients

Phase 4, open-label trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Number of Participants With Grade 3 or 4 Adverse Events (AEs), Grade 5 AEs, AEs Lead to Treatment Discontinuation, Serious AEs (SAEs)- All Causality up to 52.3 months and Number of Participants With Grade 3 or 4 AEs, Grade 5 AEs, AEs Leading to Treatment Discontinuation and SAEs- Treatment Related up to 52.3 months. Started Jan 2019; status: terminated.